PressNovember 15, 2022 Field Trip Announces the Launch of Freedom by Field Trip™, a First-of-Its-Kind Ketamine Therapy Program
PressNovember 15, 2022 Beckley Psytech Successfully Completes Phase I Clinical Study of Lead Candidate BPL-003, a Novel Benzoate Formulation Of 5-MeO-DMT
PressNovember 15, 2022 Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
PressNovember 14, 2022 Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
PressNovember 14, 2022 PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
PressNovember 14, 2022 Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results
PressNovember 14, 2022 Revitalist and Wake Network Announce Joint Venture Partnership to Open Psychedelic Clinics and Retreats in the United States
PressNovember 14, 2022 Psychedelic-Assisted Therapy Company Better U Creates Military Liaison Officer Position to Help Expand Access to Veterans
PressNovember 14, 2022 TRIPSITTER CLINIC LTD. ANNOUNCES THE CLOSING OF ASSETS ACQUISITION DEAL WITH RECONCIOUS MEDICAL AND APPOINTMENT OF DR. MARK BRAUNSTEIN AS CHAIRMAN
PressNovember 11, 2022 Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
PressNovember 11, 2022 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
PressNovember 10, 2022 Filament Health Announces Third Quarter 2022 Financial Results and Operational Highlights
PressNovember 10, 2022 GoodCap Pharmaceuticals and the University of Toronto Awarded NSERC Alliance Grant for Ongoing Research of Low-Dose Psilocybin Drug Formulas Targeting Inflammation and Depressive Disorders
PressNovember 10, 2022 Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference
PressNovember 10, 2022 Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
PressNovember 10, 2022 Irwin Naturals Looks to Add Pacific Northwest Ketamine Clinic to Its National Footprint
PressNovember 9, 2022 Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin
